Several studies have shown that anti-NXP2 antibodies are associated with peripheral edema, muscle weakness, myalgia, dysphagia, calcinosis, and rash, and have a favorable prognosis.[24–26] Our study only found that patients positive for anti-NXP2 antibodies showed more symptoms of muscle involvement such as muscle weakness (P = .002), muscle pain (P = .003), dysphagia (P = .001), and a lower probability of comorbid rashes than other antibodies. Here, MORC3 is linked to calcinosis.